Status:
COMPLETED
Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients
Lead Sponsor:
IHU Strasbourg
Conditions:
Hepatocellular Carcinoma
Chronic Liver Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
By 2030, hepatocellular carcinoma (HCC) will become the second leading cause of cancer-related death, accounting for more than one million deaths per year according to the World Health Organization. ...
Detailed Description
By 2030, hepatocellular carcinoma (HCC) will become the second leading cause of cancer-related death, accounting for more than one million deaths per year according to the World Health Organization. ...
Eligibility Criteria
Inclusion
- Men or women over 18 years of age.
- Patients referred by their hepatologist within the framework of ultrasound screening according to the EASL hepato-cellular carcinoma screening recommendations.
- Non-cirrhotic F3 hepatopathy of any cause according to an individual assessment of the risk of hepatocarcinoma.
- Cirrhosis from any cause, non viral or virologically cured (HCV) or controlled (HBV).
- Patient with hepatopathy proven by histological evidence or confirmed by an expert committee based on clinical, biological, ultrasound (hepato-cellular insufficiency, portal hypertension) and elastographic criteria.
- Patient able to receive and understand the information relating to the study and to give his/her written informed consent.
- Patient affiliated to the French social security system.
Exclusion
- History of hepatocarcinoma
- Patient with non-cirrhotic viral B hepatopathy or uncontrolled (HBV) or uncured (HCV) viral cirrhosis.
- Patient under protection of justice, guardianship or trusteeship.
- Patient in a situation of social fragility.
- Patient subject to legal protection or unable to express consent
Key Trial Info
Start Date :
September 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 14 2024
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04802954
Start Date
September 1 2021
End Date
February 14 2024
Last Update
December 18 2024
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Angers
Angers, France, 49100
2
Hôpital Avicenne
Bobigny, France, 93000
3
Hôpital Beaujon
Clichy, France, 92110
4
Hospices Civils de Lyon, Hôpital Edouard Herriot
Lyon, France, 69003